ArticleFrontiers in oncology2026
Other primary malignancies are associated with inferior survival in multiple myeloma: a single-center matched retrospective cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Other primary malignancies (OPMs) may complicate diagnostic assessment, treatment sequencing, and prognostic evaluation in multiple myeloma (MM). This study characterized the spectrum and timing of OPMs and evaluated their association with overall survival (OS). Methods: We retrospectively screened 461 unique patients with MM treated or followed at a single center between August 8, 2019, and June 6, 2026. Patients with OPMs were categorized as OPM-first, synchronous, or MM-first and matched 1:2 with patients without OPMs by sex, age at MM diagnosis, and year of MM diagnosis. OS was evaluated using Kaplan-Meier analysis, matched-set-stratified log-rank testing, and stratified Cox regression. Results: Twenty-seven patients had OPMs, corresponding to a crude proportion of 5.9%. Lung cancer (37.0%) and prostate cancer (18.5%) were the most common OPMs. Ten patients (37.0%) were classified as OPM-first, 12 (44.4%) as synchronous, and 5 (18.5%) as MM-first. OPMs affected MM management in 29.6% of patients, whereas MM or anti-myeloma treatment affected OPM management in 18.5%; treatment was modified because of documented or anticipated overlapping toxicities in 29.6%. Median OS was 46.2 months in cases and was not reached in matched controls. OPMs were associated with inferior OS in the stratified Cox analysis (hazard ratio, 3.92; 95% CI, 1.35-11.37; Conclusion: Lung and prostate cancers were the most common OPMs in this cohort, highlighting the need for heightened clinical attention to these malignancies in patients with MM. The presence of an OPM was associated with inferior OS; however, this finding should be interpreted cautiously because of the small sample size and marked tumor heterogeneity. When both malignancies require active treatment, multidisciplinary assessment is important to determine treatment priority according to disease activity, treatment urgency, and the patient's overall condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.